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We hypothesize that crack cocaine is independently as-
sociated with smear-positive tuberculosis (TB). In a case–
control study of TB in London, 19 (86%) of 22 crack cocaine 
users with pulmonary TB were smear positive compared 
with 302 (36%) of 833 non–drug users. Respiratory dam-
age caused by crack cocaine may predispose drug users 
to infectivity.   
T
uberculosis (TB) has reemerged as a public health 
problem in London, and drug users are at high risk 
of contracting and spreading the disease (1). The United 
Kingdom has seen a substantial increase in the prevalence 
of drug use in the past decade, particularly crack cocaine 
use (2). Numbers of crack cocaine users assessed while 
in police custody in London increased 3-fold from 1993 
through 2003 (3). There are an estimated 46,000 crack co-
caine users in London; most also use opiates (4). Evidence 
to directly link risk for TB with crack cocaine use is lack-
ing, although an association with tuberculin positivity has 
been shown. Increased exposure risk is considered largely 
attributable to social and lifestyle factors including home-
lessness, imprisonment, and drug and alcohol abuse (5). 
Drug users are commonly immunocompromised through 
HIV infection and malnutrition, resulting in increased risk 
for TB infection and rapid progression to active disease.
Habitually smoking crack cocaine causes pulmonary 
damage (crack lung) (Figure). Consequently, alveolar 
macrophage function and cytokine production is impaired, 
which may enhance susceptibility to infectious diseases 
(6). Mycobacterium tuberculosis is an intracellular patho-
gen that begins the disease process after a person inhales 
bacilli into the terminal bronchi and pulmonary alveoli (7). 
Alveolar epithelial cells likely resist invasion by M. tuber-
culosis bacilli, enabling resident alveolar macrophages and 
dendritic cells sufﬁ  cient time to traverse the epithelium and 
phagocytose potential invading microbes (8). Several pul-
monary complications are associated with the inhalation of 
crack cocaine (e.g., intensive cough, hemoptysis, shortness 
of breath, chest pain, acute bilateral pulmonary inﬁ  ltrates, 
thermal airway injury, pneumothorax and noncardiogenic 
pulmonary edema, production of carbonaceous sputum, 
and exacerbation of asthma) (9). Collectively, these com-
plications have been reported as crack syndrome (10). We 
hypothesize that crack cocaine use increases the risk for 
smear-positive pulmonary TB and that a component of this 
risk relates to lung damage caused by crack cocaine inhala-
tion. 
The Study
Detailed clinical and social data were collected by case 
managers for all TB patients undergoing treatment in Lon-
don on July 1, 2003. The study was approved by the Met-
ropolitan Multicentre Research Ethics Committee–United 
Kingdom. Analyses were restricted to pulmonary patients 
15–60 years of age (n = 970). We used univariate analyses 
to compare the characteristics of crack cocaine users, other 
hard-drug users (predominantly heroin users but excluding 
those who used only alcohol and marijuana), and those not 
known to use drugs. A separate category was included for 
hard-drug users not known to use crack cocaine to have 
a group with comparable levels of social deprivation, ad-
diction related problems, and difﬁ  culty in accessing health 
services. To test the hypothesis that smear positivity at di-
agnosis was associated with crack cocaine use, we used a 
multivariate model with backwards elimination to exclude 
variables that did not make a signiﬁ  cant contribution to the 
model. Variables initially included are shown in Table 1; 
the ﬁ  nal model is shown in Table 2.
TB patients who used crack cocaine were predomi-
nantly 20–49 years of age. Crack cocaine users and other 
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drug users were signiﬁ  cantly more likely than non–drug us-
ers to have been born in the United Kingdom, of white or 
black Caribbean ethnic origin, homeless, alcohol abusers, 
or have a history of imprisonment. Non–crack drug users 
tended to have the longest delays between diagnosis and 
treatment and crack users the shortest, but this tendency did 
not reach signiﬁ  cance (Table 1). Crack cocaine users were 
statistically signiﬁ  cantly more likely to seek treatment at 
emergency departments, to adhere poorly to treatment regi-
men, or default from treatment altogether. Drug users were 
also more likely to have isoniazid-resistant disease. Among 
crack cocaine users this was primarily related to a large 
outbreak of isoniazid-resistant TB (11).
Among crack cocaine users, diagnosis showed that 
86% were smear positive compared with 36% of patients 
not known to use drugs (relative risk [RR] 2.4, 95% con-
ﬁ  dence interval [CI] 2.0–2.9), p<0.001) and 59% of drug 
users not known to use crack cocaine (RR 1.6, 95% CI 1.4–
2.0, p<0.001). Multivariate analysis showed that the risk 
for smear-positive disease was higher for drug users than 
for those not known to use drugs (odds ratio [OR] 1.9, 95% 
CI 1.2–3.0, p = 0.007) and highest in crack cocaine users 
(OR 6.6, 95% CI 1.8–24.3, p = 0.005). Other signiﬁ  cant 
risk factors for smear positivity were being of black Ca-
ribbean ethnicity, having multidrug-resistant disease, and 
seeking treatment at an emergency department. When the 
multivariate model was restricted to include only hard-drug 
users, crack cocaine users were still signiﬁ  cantly more like-
ly than other drug users to be smear positive (p = 0.02).
Conclusions
Smear-positive disease is 2.4 times more likely to be 
diagnosed in crack cocaine users than in non–drug users, 
whereas hard-drug users not known to use crack cocaine are 
1.6 times more likely to be diagnosed with smear-positive 
disease. Crack cocaine users were signiﬁ  cantly more likely 
than other drug users to be smear positive on diagnosis.
The increased risk for smear-positive disease in crack 
cocaine users was not due to diagnostic delays. Hard-drug 
users who were not conﬁ  rmed as crack cocaine users had 
the longest diagnostic delays. Crack cocaine users had the 
shortest diagnostic delays, potentially attributable to rapidly 
progressive, debilitating disease. Crack cocaine users were 
also more likely to seek treatment at an emergency depart-
ment rather than primary care services. Again, the choice of 
healthcare service may be related to the severity of disease. 
Symptom duration before diagnosis is difﬁ  cult to measure, 
especially among drug users. We included non–crack drug 
Table 1. Univariate analysis of drug-using and non–drug-using patients with pulmonary TB in London, United Kingdom, 2003–2004* 
 Variable 









cocaine user), n = 22, 
no. (%)  p value 
Gender  <0.0001
  Male   445 (54.1)  99 (86.8)  12 (54.6) 
  Female  377 (45.9)  15 (13.2)  10 (45.5) 
Ethnicity  <0.0001
  White  142 (17.1)  54 (47.0)  5 (22.7) 
  Black African  344 (41.5)  25 (21.7)  5 (22.7) 
  Black Caribbean  32 (3.9)  15 (13.0)  9 (40.9) 
  South Asian  244 (29.4)  17 (14.8)  0
  Other  68 (8.2)  4 (3.5)  3 (13.6) 
Born in the United Kingdom  162 (19.6)  62 (54.9)  14 (63.7)  <0.0001
Previous TB  78 (9.4)  25 (21.7)  5 (22.7)  <0.0001
Previous TB past 2 years (relapsed)  36 (4.3)  19 (16.5)  4 (18.2)  <0.0001
Known HIV+  95 (11.4)  9 (7.8)  3 (13.6)  0.478
Delay in diagnosis >3 mo 109 (13.1) 19 (16.5) 2 (9.1) 0.499
Sought treatment at ED   126 (15.1)  32 (27.8)  10 (45.6)  <0.0001
Cough during initial examination 589 (70.7) 99 (86.1) 19 (86.40 0.001
Sputum smear positive at diagnosis  302 (36.3)  68 (59.1)  19 (86.4)  <0.0001
MDR 32 (3.8) 7 (6.1) 0 0.333
Linked to known INH resistance outbreak 9 (1.1) 10 (8.7) 11 (50.0) <0.0001
INH resistance (not outbreak) 54 (6.5) 11 (9.6) 1 (4.5) 0.783
Treated with DOT from start  74 (9.0)  19 (16.5)  6 (27.3)  0.001
Nonadherent to treatment in first 2 mo   125 (15.0)  59 (51.3)  15 (68.2)  <0.0001
Lost to follow-up   19 (2.3)  12 (10.4)  6 (27.3)  <0.0001
Homeless 37 (4.4) 22 (19.1) 13 (59.1) <0.0001
Mental health problems 28 (3.4) 27 (23.5) 9 (40.9) <0.0001
Imprisoned during current episode of TB 9 (1.1) 22 (19.1) 14 (63.6) <0.0001
*TB, tuberculosis; ED, emergency department; MDR, multidrug resistant; INH, isoniazid; DOT, directly observed therapy.         
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users as a comparison group because they have a similar 
social proﬁ  le and similar access to healthcare. Therefore, 
we are conﬁ  dent that the extremely high levels of smear 
positivity on diagnosis in crack cocaine users are not due to 
a long duration of clinical illness preceding diagnosis.
In the multivariate model, crack cocaine use remains 
strongly associated with smear-positive disease after con-
trolling for a wide variety of other potential confounders. 
Other risk factors include ethnicity (drug use was common 
among black Caribbean patients and may have been under-
reported); treatment at an emergency department (possibly 
a marker of disease severity); and multidrug-resistant dis-
ease. We are uncertain why multidrug-resistant cases were 
more likely to be smear-positive on diagnosis; however, 
previous studies have found that cavitary disease is a risk 
factor for drug resistance (12).
 The fact that smear positivity was signiﬁ  cantly more 
prevalent in patients known to use crack cocaine when 
compared with other hard-drug users suggests that this ad-
ditional risk may be attributable to a biological component. 
Plausible biological mechanisms to explain the increased 
risk of smear-positive disease include poor alveolar mac-
rophage antimicrobial activity in crack cocaine users due to 
decreased inducible nitric oxide synthase activity (13) and 
direct effects on the lung (10).
It is likely that a proportion of hard-drug users were 
incorrectly classiﬁ  ed as not using crack cocaine due to non-
disclosure. This would reduce the apparent differences in 
levels of smear positivity between the groups. Neverthe-
less, despite relatively small numbers of known crack co-
caine users, there is a signiﬁ  cantly (p = 0.02) higher propor-
tion of smear-positive disease in these patients compared 
with other hard-drug users. 
Previous studies have shown TB transmission associ-
ated with crack cocaine use (14). Persons frequenting crack 
houses are likely to have multiple risk factors for active 
pulmonary TB. Prolonged sharing of closed and conﬁ  ned 
airspace, intensive coughing, and other acute pulmonary 
complications of crack cocaine inhalation promote trans-
mission. Drug users are more likely than non–drug users to 
default treatment, to remain infectious for prolonged peri-
ods after diagnosis, and to acquire drug-resistant TB (15). 
We studied smear status at diagnosis to exclude the effect 
of poor treatment adherence. 
Our study suggests a dangerous synergy between TB 
and crack cocaine. Users may experience addiction-related 
problems that complicate access to healthcare and aggra-
vate transmission, possibly aggravated by a biological driv-
er that may increase susceptibility to infection and progres-
sion to infectious disease. Additional studies are needed to 
investigate the possible biological role of crack cocaine in 
the development of infectious forms of TB. 
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